<?xml version="1.0" encoding="UTF-8"?><rss version="2.0">
<channel>
  <title>Nyheter om: Trials</title>
  <link>https://www.pressen.se/</link>
  <description>På Pressen.se kan du söka efter artiklar i svenska medier.</description>
    <pubDate>Fri, 23 Oct 2026 17:30:00 GMT</pubDate>
  <item>
    <title>Hansa Biopharma meddelar att positiva Idefirix PAES-resultat har presenterats under sessionen High-Impact Clinical Trials vid ASN Kidney Week</title>
    <pubDate>Fri, 23 Oct 2026 17:30:00 GMT</pubDate>
    <link>https://www.pressen.se/1371617556.html</link>
    <description>
	Patientöverlevnad med fungerande transplantat efter 12 månader uppgick till 90 procent, vilket är kliniskt betydelsefullt
	Transplantat- och patientöverlevnaden uppgick till 92 respektive 98 procent
	Idefirix tolererades generellt väl och säkerhetsprofilen var i linje med tidigare kliniska studier

Lund, 23 oktober 2026. Hansa Biopharma AB, ”Hansa” (Nasdaq Stockholm: HNSA), meddelar idag att data från den europeiska bekräftande uppföljningsstudien efter godkännande (Post-Authorization Efficacy and Safety-studie, PAES) av Idefirix® (imlifidase) har presenterats muntligt under sessionen High-Impact Clinical Trials vid American Society of Nephrologys (ASN) kongress Kidney Week 2026 i Denver. Abstractet ”FR-OR103 Post-Authorization Efficacy and Safety (PAES): An Open-Label Post-Authorization Trial of 50 Imlifidase Crossmatch-Positive Deceased-Donor Kidney Transplants in Europe” var utvalt som ett Late-Breaking Abstract till kongressen.</description>
    <source>Dagens PS</source>
  </item>


  <item>
    <title>Pelicot-fallet skildras på Dramaten: ”Berättelse om vår civilisation”</title>
    <pubDate>Tue, 09 Dec 2025 05:00:00 GMT</pubDate>
    <link>https://www.pressen.se/1253055051.html</link>
    <description>Kungliga Dramatens scen förvandlas till en rättssal när föreställningen The Pelicot Trials gästspelar i Stockholm. Regissören Milo Rau, känd för att iscensätta verkliga rättegångar, vill med pjäsen skildra människans kapacitet och citerar Hanna Arendts idé om den banala ondskan.Föreställningen reflekterar över människans fria vilja och lyfter ämnen som sexuella övergrepp och våld i ensemblens fyra timmar långa framträdande..</description>
    <source>SR</source>
  </item>
  <item>
    <title>Schweiziskt bolag avbryter alzheimersstudie</title>
    <pubDate>Wed, 05 Mar 2025 08:02:02 GMT</pubDate>
    <link>https://www.pressen.se/1139968079.html</link>
    <description>Det schweiziska forskningsbolaget Asceneuron avbryter en fas 2-studie med läkemedelskandidaten ASN51 vid behandling av Alzheimers sjukdom. Det framgår av en uppdatering på Clinical Trials hemsida..</description>
    <source>DI</source>
  </item>
  <item>
    <title>Two in-depth features about Hamlet BioPharma in the prestigious CEO world magazines and pulse 2.0 business news website</title>
    <pubDate>Mon, 04 Nov 2024 09:33:53 GMT</pubDate>
    <link>https://www.pressen.se/1092726281.html</link>
    <description>Hamlet BioPharma, ticker HAMLET B, the innovative pharmaceutical company, which develops new therapies against cancer and infections, is pleased to inform that the CEO World Magazine, renowned for its focus on high-level executives and influential business leaders, has featured Hamlet BioPharma in their latest Company Spotlight. They highlight Hamlet’s recent clinical trials and innovative approach merging groundbreaking research with a strong business vision..</description>
    <source>DI</source>
  </item>
  <item>
    <title>SyntheticMR and SimonMed Expand Trials of Synthetic MRI Testing and Announce Upcoming Expansion of Synthetic Availability from SyntheticMR’s SyMRI NEURO Software at SimonMed Facilities.</title>
    <pubDate>Wed, 17 Apr 2024 08:15:00 GMT</pubDate>
    <link>https://www.pressen.se/1023181319.html</link>
    <description>SimonMed Imaging (&quot;SimonMed&quot;), one of the largest outpatient medical imaging providers and radiology practices in the United States, announces the continuation of its partnership with SyntheticMR for research as well as the upcoming expansion of synthetic availability from SyntheticMR’s SyMRI NEURO software at its facilities..</description>
    <source>DI</source>
  </item>
  <item>
    <title>OPINION: Melodifestivalen shows multilingualism isn&#039;t a threat to Swedish</title>
    <pubDate>Mon, 11 Mar 2024 11:59:05 GMT</pubDate>
    <link>https://www.pressen.se/1013933384.html</link>
    <description>
            Far from the polarising political debate, Sweden&#039;s Eurovision trials showed viewers the real, human side of life in many languages, writes linguist Sarah Campbell..</description>
    <source>The Local</source>
  </item>
  <item>
    <title>Antimicrobial peptide therapy for tuberculosis infections</title>
    <pubDate>Wed, 20 Dec 2023 12:27:35 GMT</pubDate>
    <link>https://www.pressen.se/995346470.html</link>
    <description>Hamlet BioPharma, the innovative pharmaceutical company currently advancing several phase II trials targeting infectious diseases and cancer, along with an extensive project and patent portfolio, is delighted to announce progress for the tuberculosis project. A PhD thesis entitled ‘’Antimicrobial peptide therapy for tuberculosis infections’’, from the group of Professor G. Godaly, was successfully defended by Komal Umashankar Rao..</description>
    <source>DI</source>
  </item>
  <item>
    <title>Strong anti-tumor effects detected in Alpha1H treated patients, for a combination of clinical and molecular endpoints</title>
    <pubDate>Mon, 16 Oct 2023 14:11:34 GMT</pubDate>
    <link>https://www.pressen.se/954988605.html</link>
    <description>Hamlet BioPharma, the pharmaceutical company with a strong portfolio of projects for the treatment of cancer and infections, announces the results for the investigational drug Alpha1H, in patients with bladder cancer. The analysis of the combined data set from two clinical study parts has now been completed and submitted for publication. Treatment resulted in a significant reduction in tumor size in 82% of tumors treated with the higher and 45% of tumors treated with the lower dose of Alpha1H.</description>
    <source>DI</source>
  </item>
  <item>
    <title>Bioarctics partner ska presentera nya data vid alzheimerkonferens</title>
    <pubDate>Mon, 16 Oct 2023 06:14:45 GMT</pubDate>
    <link>https://www.pressen.se/954712836.html</link>
    <description>Bioarctics partner Eisai kommer att presentera nya data från fas 3-studien Clarity AD med antikroppen lecanemab vid alzheimerkongressen CTAD (Clinical Trials on Alzheimer&#039;s Disease). .</description>
    <source>DI</source>
  </item>
  <item>
    <title>3Z and biotx.ai Forge Partnership to Advance ADHD Drug Development Using AI Modelling</title>
    <pubDate>Fri, 18 Aug 2023 14:26:23 GMT</pubDate>
    <link>https://www.pressen.se/906097845.html</link>
    <description>Reykjavik-based drug discovery company, 3Z, and Germany/US-based causal AI firm, biotx.ai, have joined forces in a strategic partnership aimed at revolutionizing ADHD drug development. By leveraging advanced AI modelling techniques, the collaboration seeks to bridge the gap between animal studies and human clinical trials, enabling a more efficient and accurate translation of promising therapeutics..</description>
    <source>DI</source>
  </item>
</channel>
</rss><!-- CR: cache is set: Sidan laddades på 0.11177802085876 s -->